JP7352569B2 - 肝細胞癌の治療のための併用療法 - Google Patents

肝細胞癌の治療のための併用療法 Download PDF

Info

Publication number
JP7352569B2
JP7352569B2 JP2020558858A JP2020558858A JP7352569B2 JP 7352569 B2 JP7352569 B2 JP 7352569B2 JP 2020558858 A JP2020558858 A JP 2020558858A JP 2020558858 A JP2020558858 A JP 2020558858A JP 7352569 B2 JP7352569 B2 JP 7352569B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
methylureido
dimethoxyphenyl
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020558858A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019139977A5 (https=
JP2021512140A (ja
JP2021512140A5 (https=
Inventor
アナンド セルバラジ，
ピーター スミス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of JP2021512140A publication Critical patent/JP2021512140A/ja
Publication of JPWO2019139977A5 publication Critical patent/JPWO2019139977A5/ja
Publication of JP2021512140A5 publication Critical patent/JP2021512140A5/ja
Priority to JP2023149903A priority Critical patent/JP7665700B2/ja
Application granted granted Critical
Publication of JP7352569B2 publication Critical patent/JP7352569B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2020558858A 2018-01-10 2019-01-09 肝細胞癌の治療のための併用療法 Active JP7352569B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023149903A JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862615848P 2018-01-10 2018-01-10
US62/615,848 2018-01-10
PCT/US2019/012886 WO2019139977A1 (en) 2018-01-10 2019-01-09 Combination therapies for the treatment of hepatocellular carcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023149903A Division JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Publications (4)

Publication Number Publication Date
JP2021512140A JP2021512140A (ja) 2021-05-13
JPWO2019139977A5 JPWO2019139977A5 (https=) 2022-01-18
JP2021512140A5 JP2021512140A5 (https=) 2022-01-18
JP7352569B2 true JP7352569B2 (ja) 2023-09-28

Family

ID=65411938

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558858A Active JP7352569B2 (ja) 2018-01-10 2019-01-09 肝細胞癌の治療のための併用療法
JP2023149903A Active JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023149903A Active JP7665700B2 (ja) 2018-01-10 2023-09-15 肝細胞癌の治療のための併用療法

Country Status (13)

Country Link
US (1) US11833119B2 (https=)
EP (2) EP3737377B1 (https=)
JP (2) JP7352569B2 (https=)
KR (2) KR102811519B1 (https=)
CN (1) CN111787922A (https=)
AU (1) AU2019206480A1 (https=)
BR (1) BR112020014112A2 (https=)
CA (1) CA3088292A1 (https=)
IL (1) IL275981A (https=)
MA (1) MA51570A (https=)
MX (1) MX2020007375A (https=)
SG (1) SG11202006617RA (https=)
WO (1) WO2019139977A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533903A (ja) * 2020-05-15 2023-08-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｆｇｆｒ４阻害剤の経口製剤によるがんの治療方法
CN117479958A (zh) * 2022-05-30 2024-01-30 石药集团中奇制药技术（石家庄）有限公司 用于治疗癌症的药物组合和药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160089365A1 (en) 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
PL1698623T3 (pl) 2003-12-25 2015-08-31 Eisai R&D Man Co Ltd Postać krystaliczna soli 4-(3-chloro-4-(cyklopropyloaminokarbonylo)aminofenoksy)-7-metoksy-6-chinolinokarboksamidu lub jej solwatu i sposoby ich wytwarzania
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
JP2015505562A (ja) * 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
KR102265952B1 (ko) 2013-06-26 2021-06-16 에자이 알앤드디 매니지먼트 가부시키가이샤 암 치료 병용요법으로서 에리불린 및 렌바티닙의 용도
MX378288B (es) 2013-10-18 2025-03-10 Eisai R&D Man Co Ltd Inhibidores de pirimidina del fgfr4.
MX373150B (es) * 2014-03-26 2020-04-21 Astex Therapeutics Ltd Combinaciones de un inhibidor del factor de crecimiento de fibroblasto (fgfr) y un inhibidor del receptor del factor de crecimiento 1 similar a insulina (igf1r).
SG10201810057UA (en) 2015-04-14 2018-12-28 Eisai R&D Man Co Ltd Crystalline fgfr4 inhibitor compound and uses thereof
CN107304188A (zh) * 2016-04-20 2017-10-31 成都融科博海科技有限公司 一种氘代激酶选择性抑制剂及其应用
EP3454898B1 (en) * 2016-05-10 2021-11-10 Eisai R&D Management Co., Ltd. Drug combinations for reducing cell viability and/or cell proliferation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160089365A1 (en) 2014-09-25 2016-03-31 Eisai R&D Management Co., Ltd. Immunostimulatory compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Research，2017年，77(24)，pp.6999-7013
Liver Cancer，2017年，6(3)，pp.177-184

Also Published As

Publication number Publication date
US20200360371A1 (en) 2020-11-19
US11833119B2 (en) 2023-12-05
CN111787922A (zh) 2020-10-16
MX2020007375A (es) 2020-11-09
JP2023175825A (ja) 2023-12-12
JP7665700B2 (ja) 2025-04-21
RU2020126673A (ru) 2022-02-10
WO2019139977A1 (en) 2019-07-18
KR20250073570A (ko) 2025-05-27
KR20200121302A (ko) 2020-10-23
AU2019206480A1 (en) 2020-08-27
MA51570A (fr) 2020-11-18
EP3737377A1 (en) 2020-11-18
SG11202006617RA (en) 2020-08-28
BR112020014112A2 (pt) 2020-12-01
IL275981A (en) 2020-08-31
CA3088292A1 (en) 2019-07-18
EP4667005A2 (en) 2025-12-24
JP2021512140A (ja) 2021-05-13
EP3737377B1 (en) 2025-10-08
KR102811519B1 (ko) 2025-05-22
EP4667005A3 (en) 2026-02-18
RU2020126673A3 (https=) 2022-04-19

Similar Documents

Publication Publication Date Title
JP7190425B2 (ja) 肝細胞癌の治療のための併用療法
JP7665700B2 (ja) 肝細胞癌の治療のための併用療法
KR102517650B1 (ko) 유방암의 치료를 위한 조합물 요법
WO2011127235A1 (en) Combination therapy for the treatment of dementia
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
JP7704690B2 (ja) 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20201006

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201006

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230915

R150 Certificate of patent or registration of utility model

Ref document number: 7352569

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150